{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000024","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.637832+00:00","generated_at":"2026-06-18T23:21:43.926956+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent BioSolutions Q4 2022 net loss $88M, revenue $331M (-54% YoY); FY2023 guidance issued","bullets":["Q4 2022 total revenues $330.7M vs $723.2M in Q4 2021; net loss $88.0M vs net income $189.3M.","Full year 2022 revenues $1,120.9M (-37% YoY); net loss $223.8M vs net income $230.9M.","FY2023 guidance: revenues $1.1-1.2B, adjusted EBITDA $75-125M, adjusted gross margin 41-44%.","Agreed to sell travel health business to Bavarian Nordic for up to $380M; FDA priority review for NARCAN OTC.","Eliminated 132 positions with annualized savings >$60M; DoD RSDL contract valued up to $379.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000024","json":"https://secwatch.observer/filing/0001367644-23-000024.json","markdown":"https://secwatch.observer/filing/0001367644-23-000024.md","text":"https://secwatch.observer/filing/0001367644-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/ebs-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:21:43.926956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f95e428b6dde25fab8318f60aa5fc54f07716f2","claim":"Emergent BioSolutions Inc. reported Full Year 2022 results: revenue $1,120.9, net income $(223.8), EPS $(4.47). Guidance initiated.","evidence_excerpt":"Full Year 2022 vs. Full Year 2021 ($ in millions, except per share amounts) Full Year 2022 Full Year 2021 % Change Total Revenues $1,120.9 $1,792.7 (37)% Net Income (Loss) $(223.8) $230.9 * Net Income (Loss) per Diluted Share $(4.47) $4.27 *","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$1,120.9"},{"label":"Net income","value":"$(223.8)"},{"label":"EPS","value":"$(4.47)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"97ce97101afad39ed63477447823e9816d31c06f","claim":"Emergent BioSolutions Inc. reported Q4 2022 results: revenue $330.7, net income $(88.0), EPS $(1.76). Guidance initiated.","evidence_excerpt":"Q4 2022 vs. Q4 2021 ($ in millions, except per share amounts) Q4 2022 Q4 2021 % Change Total Revenues $330.7 $723.2 (54)% Net Income (Loss) $(88.0) $189.3 * Net Income (Loss) per Diluted Share $(1.76) $3.50 *","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2022"},{"label":"Revenue","value":"$330.7"},{"label":"Net income","value":"$(88.0)"},{"label":"EPS","value":"$(1.76)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}